- Record: found
- Abstract: found
- Article: not found
Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.
Wendy Onstenk
1 ,
Anieta M Sieuwerts
2 ,
Jaco Kraan
2 ,
Mai Van
2 ,
Annemieke J M Nieuweboer
2 ,
Ron H J Mathijssen
2 ,
Paul Hamberg
3 ,
Hielke J Meulenbeld
4 ,
Bram De Laere
5 ,
Luc Y Dirix
5 ,
Robert J van Soest
6 ,
Martijn P Lolkema
2 ,
John W M Martens
2 ,
Wytske M van Weerden
6 ,
Guido W Jenster
6 ,
John A Foekens
2 ,
Ronald de Wit
2 ,
Stefan Sleijfer
2
Dec 2015
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Androgen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs) from patients with metastatic castration-resistant prostate cancer (mCRPC) was recently demonstrated to be associated with resistance to abiraterone and enzalutamide. Cabazitaxel might, however, remain effective in AR-V7-positive patients.